BAY 87-2243 NEW
| Price | $38 | $60 | $109 |
| Package | 2mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: BAY 87-2243 | CAS No.: 1227158-85-1 |
| Purity: 99.77% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | BAY 87-2243 |
| Description | BAY 87-2243 is a potent and selective inhibitor of hypoxia-inducible factor-1 (HIF-1). |
| Cell Research | To evaluate the cytotoxicity of BAY 87-2243, 2.000 cells of the respective cell lines are seeded in 96-well plates and cultured in the appropriate growth medium containing 10% FCS. BAY 87-2243 at various concentrations is added at 24 h after seeding for additional 48 h and cell viability is determined using Cell Titer Glow Assay.(Only for Reference) |
| In vitro | BAY87-2243 (administered orally at 4 mg/kg) reduced tumor weight, HIF-1α protein, and HIF-1 target gene expression levels in an H460 xenograft mouse model. |
| In vivo | In hypoxic lung cancer H460 cells, BAY 87-2243 inhibits the expression of HIF target genes and suppresses the accumulation of HIF-1α protein. It impairs cell proliferation by interfering with mitochondrial function under glucose consumption. Additionally, BAY 87-2243 inhibits the reporter gene activity of HIF-1 and the expression of CA9 protein, with IC50 values of 0.7 nM and 2 nM, respectively. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 52.55 mg/mL (100 mM), Sonication and heating are recommended. |
| Keywords | Ferroptosis | inhibit | BAY 87-2243 | HIFs | HIF-PH | HIF/HIF Prolyl-Hydroxylase | Inhibitor | BAY 872243 | Hypoxia-inducible factors | BAY 87 2243 |
| Inhibitors Related | TBHQ | Acetylcysteine | Butylated hydroxytoluene | α-Vitamin E | Sorafenib | Curcumin | Glucosamine | Hydroxycitric acid tripotassium hydrate | Artemisinin | L-Cystine | L-Glutamic acid monosodium salt | Coenzyme Q10 |
| Related Compound Libraries | Bioactive Compound Library | HIF-1 Signaling Pathway Compound Library | Anti-Cancer Metabolism Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $82.00/2mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-10-23 | |
| $1.00/1g |
VIP1Y
|
Apeloa production Co.,Limited
|
2024-06-18 | |
| $17.00/1g |
VIP5Y
|
Career Henan Chemica Co
|
2020-10-28 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY